Addex Therapeutics

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional orthosteric small molecule or biological drugs. Addexs allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addexs lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinsons disease levodopa induced...

Allosteric modulation,parkinson's disease,schizophrenia,inflammation,metabolic,diabetes,dyskinesia,anxiety,pain,depression,ptsd,alzheimer's,mglu,mglur,gaba,fsh,glp-1,tnf,and il-1

Addex therapeutics operates in the Biotechnology research industry.

Addex therapeutics's revenue is < 1m

Addex therapeutics has 11 - 50 employees.